• Masanori Abe, Kazuyoshi Okada, Noriaki Maruyama, Shiro Matsumoto, Takashi Maruyama, Takayuki Fujita, Koichi Matsumoto, and Masayoshi Soma.
• Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, and Nihon Universiyt Nerima Hikarigaoka Hospital, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo, 173-8610, Japan. mabe@med.nihon-u.ac.jp
• Expert Opin Investig Drugs. 2010 Sep 1;19(9):1027-37.

AimsBenidipine, an L-/T-type calcium channel blocker, dilates renal efferent and afferent arterioles and reduces glomerular pressure; therefore, it may exert renoprotective effects. We conducted an open-labeled randomized trial to compare the effects of benidipine with cilnidipine in hypertensive patients with chronic kidney disease (CKD).MethodsThe patients who were already being treated with angiotensin receptor blockers (ARBs) received one of the following treatment regimens: benidipine at a dose of 2 mg/day that was increased up to a dose of 8 mg/day (benidipine group; n=118) or cilnidipine at a dose of 5 mg/day that was increased up to a dose of 20 mg/day (cilnidipine group; n=115).ResultsAfter 12 months of treatment, we observed a significant and comparable reduction in the systolic and diastolic blood pressure in both groups. The urinary protein:creatinine ratio was significantly decreased in both groups after 3 months of treatment and thereafter; however, the difference between both groups was not significant after 12 months of treatment. Benidipine exerted an antiproteinuric effect to a greater extent than cilnidipine in patients with diabetes.ConclusionThe addition of benidipine as well as cilnidipine reduces urinary protein excretion in hypertensive patients with CKD who are already being administered ARBs.

38 keywords...

hide…